Status:

COMPLETED

Prophylactic Antibiotic Regimens in Tumor Surgery (PARITY)

Lead Sponsor:

McMaster University

Collaborating Sponsors:

Orthopedic Research and Education Foundation

The Physicians' Services Incorporated Foundation

Conditions:

Infection

Bone Neoplasms

Eligibility:

All Genders

12+ years

Phase:

PHASE3

Brief Summary

The Prophylactic Antibiotic Regimens in Tumor Surgery (PARITY) trial is the first ever international multi-center randomized controlled trial in bone cancer surgery. In order to avoid amputation for b...

Detailed Description

Long-bone sarcomas were historically managed with amputation. In the current era of osteosarcoma management, amputations are generally avoided by complex surgeries in which the malignancy is removed a...

Eligibility Criteria

Inclusion

  • primary bone malignancies or aggressive benign bone tumors of the femur or tibia, soft-tissue sarcomas which have invaded the femur or tibia, or oligometastatic bone disease of the femur or tibia in a patient expected to live at least one year post-operatively; and
  • treatment by surgical excision and endoprosthetic replacement of the femur or tibia.

Exclusion

  • current known Methicillin-resistant Staphylococcus Aureus (MRSA) colonization;
  • current known Vancomycin Resistant Enterococcus (VRE) colonization;
  • documented anaphylaxis or angioedema to penicillin or cefazolin (Ancef);
  • current surgical procedure is a revision surgery for implant failure or infection;
  • prior local infection within the surgical field of the affected limb;
  • current known immunologically-deficient disease conditions (not including recent chemotherapy);
  • known renal insufficiency with estimated creatinine clearance (eGRF) of less than 54 mL/min;
  • reconstruction to include structural allograft;
  • enrolled in a competing study; and
  • weight of less than or equal to 45 kg (for sites using cefuroxime only).

Key Trial Info

Start Date :

January 1 2013

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 1 2021

Estimated Enrollment :

602 Patients enrolled

Trial Details

Trial ID

NCT01479283

Start Date

January 1 2013

End Date

March 1 2021

Last Update

March 11 2021

Active Locations (54)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 14 (54 locations)

1

University of Arkansas for Medical Sciences

Little Rock, Arkansas, United States, 72205

2

Ronald Reagan UCLA Medical Center

Los Angeles, California, United States, 90404

3

Stanford University Hospital and Clinics

Redwood City, California, United States, 94063

4

UC Davis Comprehensive Cancer Center

Sacramento, California, United States, 95817